Marine Drugs (Sep 2022)

A Nutraceutical Formulation Containing Brown Algae Reduces Hepatic Lipid Accumulation by Modulating Lipid Metabolism and Inflammation in Experimental Models of NAFLD and NASH

  • Daniela Gabbia,
  • Marco Roverso,
  • Ilaria Zanotto,
  • Martina Colognesi,
  • Katia Sayaf,
  • Samantha Sarcognato,
  • Diletta Arcidiacono,
  • Alice Zaramella,
  • Stefano Realdon,
  • Nicola Ferri,
  • Maria Guido,
  • Francesco Paolo Russo,
  • Sara Bogialli,
  • Maria Carrara,
  • Sara De Martin

DOI
https://doi.org/10.3390/md20090572
Journal volume & issue
Vol. 20, no. 9
p. 572

Abstract

Read online

Recently, some preclinical and clinical studies have demonstrated the ability of brown seaweeds in reducing the risk factors for metabolic syndrome. Here, we analyzed the beneficial effect of a nutraceutical formulation containing a phytocomplex extracted from seaweeds and chromium picolinate in animal models of liver steatosis of differing severities (rats with non-alcoholic fatty liver disease (NAFLD) and its complication, non-alcoholic steatohepatitis (NASH)). This treatment led to a significant drop in hepatic fat deposition in both models (p < 0.01 vs. untreated animals), accompanied by a reduction in plasma inflammatory cytokines, such as interleukin 6, tumor necrosis factor α, and C reactive protein, and myeloperoxidase expression in liver tissue. Furthermore, a modulation of the molecular pathways involved in lipid metabolism and storage was demonstrated, since we observed the significant reduction of the mRNA levels of fatty acid synthase, diacylglycerol acyltransferases, the sterol-binding protein SREBP-1, and the lipid transporter perilipin-2, in both treated NAFLD and NASH rats in comparison to untreated ones. In conclusion, this nutraceutical product was effective in reducing liver steatosis and showed further beneficial effects on hepatic inflammation and glycemic control, which were particularly evident in rats characterized by a more severe condition, thus representing a therapeutic option for the treatment of NAFLD and NASH patients.

Keywords